CH-4051: Phase II start

Next month, Chelsea will begin a double-blind, international Phase II trial in 250 patients to evaluate once-daily 0.3, 1 or 3 mg of oral CH-4051 alone, once-daily 3 mg CH-4051 plus folate or weekly m...